Autopsy report · NCT00060554

A Safety and Efficacy Trial Evaluating the Use of Fondaparinux in Percutaneous Coronary Intervention (PCI)(63133)(WITHDRAWN)

“Drug sold to Sanofi-Aventis who sold it to GSK; OBS no longer owns study and does not have data.”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 2

Sponsor

Schering-Plough

Sponsor type

Industry

Conditions

Myocardial Infarction; Coronary Disease

Interventions

fondaparinux sodium; heparin; percutaneous coronary intervention (PCI)

Participants

300

Sites

26

Countries

Canada, France, United States

Trials that died the same way

• Panobinostat/Velcade in Multiple Myeloma
  “This study was terminated because the drug company stopped making the study drug” (59% match in meaning)
• Gedatolisib, Hydroxychloroquine or the Combination for Prevention of Recurrent Breast Cancer ("GLACIER")
  “due to business decision regarding the study drug.” (59% match in meaning)
• CMP-001 and INCAGN01949 for Patients With Stage IV Pancreatic Cancer and Other Cancers Except Melanoma
  “Study drug no longer available” (58% match in meaning)
• A Study of Maprotiline in Combination With Tamoxifen and Temozolomide for Recurrent Glioblastoma
  “One of the drugs for the study is not commercially available.” (58% match in meaning)
• P1101 in Treating Patients With Myelofibrosis
  “Study drug became commercially available” (56% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.